BESPARK
LIVE

Serial Number

79433020

Owner

bespark bio GmbH

Attorney

Jason L DeFrancesco

Filing Date

Mar 19, 2025

Add to watchlist:

No watchlists yet
View on USPTO

BESPARK Trademark

Serial Number: 79433020

BESPARK is a trademark filed by bespark bio GmbH on March 19, 2025. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently pending registration.

Owner Contact Info

bespark bio GmbH

Muthgasse 11/2

Entity Type: 98

Trademark Details

Filing Date

March 19, 2025

Registration Date

Not Registered

Goods & Services

Viral vaccines; vaccines for human use; cells for medical use; antibodies for medical purposes; pharmaceutical preparations for use in oncology or the treatment of solid tumor oncological diseases; pharmaceutical preparations and substances for use in oncology for the treatment of solid tumor oncological diseases; biological preparations for medical purposes for the treatment of solid tumor oncological diseases; chemical preparations for medical purposes, namely, for the treatment of solid tumor oncological diseases; all the foregoing excluding preparations for the diagnosis or treatment of retinal degenerative disorders, hematologic disorders, and hematologic diseases

Scientific laboratory services; scientific analytical laboratory services; technology consultation in the field of artificial intelligence; research in the field of artificial intelligence technology; computer system analysis; design of computer-simulated models; computer software design for others; biochemistry services, namely, biochemical analysis services; medical research laboratories; chemistry services, namely, research and development services in the field of chemistry; chemical laboratories; chemical analysis; conducting technical project studies, namely, conducting feasibility studies in the field of new technologies; electronic data storage; provision of research services, namely, medical research services; biomedical research services; research relating to biotechnology, namely, biotechnology research; pharmaceutical research services; bacteriological research; chemical research; medical and pharmacological research services; research and development of new products for others; scientific research and development services; pharmaceutical research and development; medical and scientific research, namely, conducting clinical trials for others; technology advisory services relating to gene therapy research; scientific research in the field of gene therapy; culturing of cells for others for scientific research purposes; research and development services relating to vaccines; research and development of vaccines and medicines; medical research; scientific research for medical purposes in the area of cancerous diseases; medical research in the field of oncology; platform as a service (PAAS) featuring computer software platforms for use in bioprocess data modeling, simulation of biopharmaceutical manufacturing processes, digital-twin modeling of cell-culture and biologics production processes, and analysis of bioprocess development data; software engineering services for data processing programs; technological consultancy services for digital transformation; technological consultancy, namely, computer technology consultancy; technological research relating to bioprocessing, biotechnology, cell-line development, process development, analytical development, product validation, biologics, biosimilars, viral vectors, vaccines, ATMPs, and bionanoparticles; chemical technological research, namely, technological research in the field of chemistry; consultancy services relating to technological research, namely, technology consultation and research in the field of biotechnology, bioprocessing, cell-line development, process development, analytical development, and biopharmaceutical product validation; technical writing; scientific research; scientific and technological services, namely, computer aided scientific research services in the field of biotechnology, bioprocessing, cell-line development, process development, analytical development, and biopharmaceutical product validation; scientific research and development; Scientific and technological services, namely, scientific research and analysis in the field of biotechnology, bioprocessing, cell-line development, process development, analytical development, and biopharmaceutical product validation; scientific research in the field of genetics and genetic engineering; scientific research in the field of genetics; biological analysis; biochemical analysis services; scientific and technological services, namely, scientific analysis in the field of biotechnology, bioprocessing, cell-line development, process development, analytical development, and biopharmaceutical product validation; consultancy in the field of scientific research, namely, scientific research consultancy; scientific and technological services, namely, scientific research, scientific analysis, scientific testing, and product validation for quality evaluation purposes in the field of biotechnology, bioprocessing, cell-line development, process development, analytical development, and biopharmaceutical product validation; testing of materials, authentication in the field of biopharmaceutical raw materials, biologics, biosimilars, viral vectors, vaccines, ATMPs, and bionanoparticles and quality control for others; research laboratory analysis services in the field of bacteriology; technical consultancy in the field of industrial research; computer programming services for the analysis of data; computer design and programming services, namely, computer programming and software design; analysis of product development, namely, product research and development; quality assurance consultancy, namely, consultancy related to quality assurance services in the field of biopharmaceutical manufacturing, bioprocessing, cell-culture processes, and biologics development; consultancy services relating to quality control, namely, Consultancy relating to inspection of food processing facilities for quality control purposes; computer aided scientific testing, namely, computer aided genetic testing for scientific research purposes; computer aided testing services, namely computer aided product safety testing; engineering testing, namely, testing of biopharmaceutical manufacturing equipment, bioreactor systems, cell-culture systems, and bioprocessing systems for scientific research and product-development purposes; conducting of quality control tests, namely, quality control testing for others; technical measuring, namely, technical measuring and testing of biopharmaceutical process parameters, namely, cell-culture performance, bioreactor process performance, product quality attributes, and analytical assay performance, all for quality assurance purposes; scientific testing services, namely, scientific testing of biopharmaceutical products, biologics, biosimilars, viral vectors, vaccines, ATMPs, bionanoparticles, cell cultures, and bioprocess materials; development and test of chemical production methods; development of measuring and testing methods, namely, development and establishment of testing specifications and procedures in the field of biopharmaceutical manufacturing, bioprocessing, cell-line development, process development, analytical development, and product validation for quality evaluation purposes; development of testing methods, namely, development and establishment of testing specifications and procedures in the field of biopharmaceutical manufacturing, bioprocessing, cell-line development, process development, analytical development, and product validation for quality evaluation purposes; design and testing for new product development; analysis and evaluation of product development, namely, product research and development evaluation for biopharmaceutical products, biologics, biosimilars, viral vectors, vaccines, ATMPs, and bionanoparticles for quality evaluation purposes; biological research laboratory services; product quality control testing, namely, quality control testing of products; product testing; product quality testing; process monitoring for quality assurance, namely, monitoring of biopharmaceutical manufacturing and bioprocessing processes for quality assurance purposes; quality assessment, namely, quality assessment services for biopharmaceutical products, biologics, biosimilars, viral vectors, vaccines, ATMPs, bionanoparticles, cell cultures, and bioprocess materials for quality evaluation purposes; quality control for others; inspection of pharmaceuticals; scientific risk assessment, namely, scientific risk assessment services for biopharmaceutical process development, analytical development, product validation, and bioprocess scale-up; scientific laboratory services relating to the production of monoclonal antibodies; research and development services in the field of antibodies; scientific research and development services in the field of antibody technology; cell culture services for scientific and research purposes, for others

Filing History

NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Jun 5, 2026 GNEN
APPROVED FOR PUB - PRINCIPAL REGISTER
Jun 5, 2026 CNSA
EXAMINER'S AMENDMENT ENTERED
Jun 5, 2026 XAEC
EXAMINERS AMENDMENT E-MAILED
Jun 5, 2026 GNEA
EXAMINERS AMENDMENT -WRITTEN
Jun 5, 2026 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 3, 2026 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 3, 2026 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jun 3, 2026 TROA
ASSIGNED TO EXAMINER
Mar 4, 2026 DOCK
REFUSAL PROCESSED BY IB
Feb 12, 2026 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Jan 23, 2026 RFCS
REFUSAL PROCESSED BY MPU
Jan 23, 2026 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Dec 20, 2025 RFCR
NON-FINAL ACTION WRITTEN
Dec 19, 2025 CNRT
NON-FINAL ACTION (IB REFUSAL) WITHDRAWN FOR REVIEW
Dec 18, 2025 RFWR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Nov 12, 2025 RFCR
NON-FINAL ACTION WRITTEN
Nov 11, 2025 CNRT
ASSIGNED TO EXAMINER
Sep 23, 2025 DOCK
APPLICATION FILING RECEIPT MAILED
Sep 22, 2025 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sep 22, 2025 NWOS
SN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB
Sep 18, 2025 SDRC